Natco Pharma Limited has reported strong financial results for the second quarter ended September 30, 2024, showcasing significant growth in both revenue and profitability.
Quarterly Financial Highlights:
- Revenue: Natco Pharma’s revenue from operations stood at ₹1,371 crore, marking a 32.1% year-on-year (YoY) growth compared to ₹1,031.4 crore in the same quarter last year. On a quarter-on-quarter (QoQ) basis, revenue grew by 5.7% from ₹1,297.1 crore in the previous quarter.
- Net Profit: The company posted a net profit of ₹676.5 crore, reflecting a substantial increase of 81.2% YoY from ₹369.0 crore in Q2 FY23-24. Sequentially, net profit rose by 10.6% from ₹604.9 crore in Q1 FY24-25.
Management Commentary: Natco Pharma attributed its robust performance to improved sales in both domestic and international markets, driven by demand for its generic and specialty pharmaceutical products. The company continues to expand its footprint globally while focusing on operational efficiencies.
The company’s impressive growth in net profit underscores its strategic efforts to enhance profitability despite a competitive environment in the pharmaceutical sector.
With these strong quarterly results, Natco Pharma remains optimistic about sustaining growth momentum, focusing on product innovation and market expansion to drive future revenue and profit growth.
Disclaimer: This article is for informational purposes only. It does not constitute financial advice.
